Cell-based and in vivo research showed that mTOR inhibitors can enhance the efficacy of various tumor immunotherapy methods by elevating PD-L1 expression in tumor cells and inhibiting the activation of T memory cells [39]. This evidence concerns the gene CD274 and neoplasm.